GenScript is the leading contract research organization in the world providing gene, peptide, protein, CRISPR, and antibody. Since its foundation in 2002, GenScript has grown exponentially through partnerships with scientists conducting fundamental life science research ... translational biomedical research, and early stage pharmaceutical development. The company is recognized as having built a best-in-class capacity and capability for biological research services, encompassing gene synthesis, peptide synthesis, custom antibody and protein engineering, and in vitro and in vivo pharmacology - all with the goal to make people and nature healthier through biotechnology by scripting possibilities.

ABSA International (ABSA) was founded in 1984 to promote biosafety as a scientific discipline and serve the growing needs of biosafety professionals throughout the world. Its goals are to provide a professional association that represents the interests and needs of practitioners ... of biological safety, and to provide a forum for the continued and timely exchange of biosafety information.

The right research model can take you further. And the emerging possibilities of genetically engineered models create opportunities to move further still. At Taconic Biosciences, we make your research goal the center of everything we do, and we go further in helping you achieve ... it. We start with the right model - even if we have to design it for your specific question - and we follow that with the research-ready colonies and streamlined licensing you need for success. At Taconic, we are here to help you get further.

Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure.​ Revvity is pushing the limits of what's possible in healthcare, with specialized focus areas in ... translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.​ With a robust global network and localized agility, we serve a diverse range of organizations from pharmaceutical and biotech, to clinical labs, academia, and governments.​ Together with our customers and partners, we are united in impact, embracing the impossible to improve lives everywhere.

Building from a strong foundation of innovation, expertise, and reliability, IDT has evolved from an oligo manufacturer to a leading genomics solutions provider. We work shoulder-to-shoulder with scientific and global health partners to enable genomics breakthroughs at scale ... Backed by Danaher, a leading life sciences and diagnostics company, we continue to invest in our operations and DNA synthesis technologies. Our vision of enabling researchers to rapidly move from the lab to life-changing advances reflects our ongoing commitment to a healthier, brighter future for all.

Lonza is one of the world's largest contract development and manufacturing organizations (CDMOs), dedicated to serving the healthcare industry. We work alongside a broad range of customers - from emerging biotechs to global pharmaceutical companies - to transform their ... therapeutic discoveries into life-saving and life-enhancing treatments for their patients. Our vision is to be the pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology and lean manufacturing. Founded in 1897 in the Swiss Alps, our business has embraced innovation and kept pace with a fast-changing world for more than 125 years. As the first and the original CDMO, we have been manufacturing medicines for more than four decades. Today we offer one of the largest Western CDMO networks with a global team of 18,500 colleagues working across more than 30 sites in five continents. Our people are united by a common purpose: to turn our customers' breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Discover more about our One Lonza strategy here. Our business is structured to meet our customers' complex needs across three synergistic Business Platforms: Integrated Biologics, Advanced Synthesis and Specialized Modalities. Our services span from early development to drug substance and drug product manufacturing, and we lead in both established and emerging technologies including mammalian biologics, small molecules, highly potent active pharmaceutical ingredients (APIs), bioconjugates, mRNA, microbial, and cell and gene. Across technologies, we deliver integrated solutions to meet our customers' needs throughout the entire treatment lifecycle. Our company generated sales of CHF 6.6 billion with a CORE EBITDA of CHF 1.9 billion in Full-Year 2024. Lonza shares are listed on the SIX Swiss Exchange and Swiss Market Index (SMI), with a secondary listing on the SGX Singapore Exchange.

Chati stands at the intersection of tradition and technology, bringing you the best of virtual and hybrid event solutions. With over two decades championing the world of events, we've seamlessly integrated the essence of in-person gatherings with the convenience of virtual ... platforms. Whether you're crafting your own unique event narrative or collaborating with our expert team, with Chati, you're always one step ahead in the event game.